Evidence map›Paper›PMID 39082675›Full record

ArticleFuture oncology (London, England)2024

Maintenance with mirvetuximab soravtansine plus bevacizumab vs bevacizumab in FRα-high platinum-sensitive ovarian cancer.

David M O'Malley, Tashanna Myers, Pauline Wimberger, Toon Van Gorp, Andres Redondo, David Cibula, Shibani Nicum, Manuel Rodrigues, Floor J Backes, Joyce N Barlin and 6 more

Abstract readClinical Trial Protocol
PubMed Full text at PMC Publisher
In one paragraph

Article in Future oncology (London, England), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Antibody-Drug Conjugates in Gynecologic Oncology: Advances, Challenges, and Future Directions.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2026
    Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Advances in Systemic Therapy for Ovarian Cancer Over the Past Decade: A Clinical and Molecular Perspective.Medical science monitor : international medical journal of experimental and clinical research · 2025
    Review
  14. Review
  15. Review
  16. Review
  17. A review of mirvetuximab soravtansine-gynx in folate receptor alpha-expressing platinum-resistant ovarian cancer.American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists · 2025
    Review
  18. Review
  19. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

David M O'MalleyGynecologic Oncology, James Cancer Center/The Ohio State University, Columbus, OH 43210, USA.ORCID 0000-0002-2828-0177
Tashanna MyersObstetrics and Gynecology, UMass Chan Medical School, Springfield, MA 01199, USA.
Pauline WimbergerGynecology and Obstetrics, and Gynecological Oncology, Carl Gustav Carus University, Technische Universität Dresden, Dresden, 01307, Germany.
Toon Van GorpDivision of Gynaecological Oncology, University Hospital Leuven, Leuven Cancer Institute, Leuven, BGOG, 3000, Belgium.
Andres RedondoServicio de Oncología Médica, Hospital Universitario La Paz-IdiPAZ, Madrid, 28046, Spain.
David CibulaDepartment of Gynaecology, Obstetrics & Neonatology, General University Hospital in Prague & First Faculty of Medicine, Charles University, Prague, 120 00;110 00, Czech Republic.
Shibani NicumOncology, University College London Hospitals NHS Foundation Trust, London, NW1 2BU, UK.
Manuel RodriguesMedical Oncology, Institut Curie., PSL Research University, INSERM U830, Paris, 75006, France.
Floor J BackesGynecologic Oncology, James Cancer Center/The Ohio State University, Columbus, OH 43210, USA.
Joyce N BarlinWomen's Cancer Care Associates, Albany Medical College, Albany, NY 12208, USA.
Sharyn N LewinGynecologic Oncology, Holy Name Medical Center, Teaneck, NJ 07666, USA.
Peter LimCenter of Hope, University of Nevada, Reno School of Medicine, Reno, NV 89557, USA.
Bhavana PothuriGynecologic Oncology, Perlmutter Cancer Center, NYU Langone Health, New York, NY 10016, USA.
Elisabeth DiverMedical Affairs, ImmunoGen, Inc., Waltham, MA 02451, USA.
Susana BanerjeeGynaecology Unit, The Royal Marsden NHS Foundation Trust & Institute of Cancer Research, London, SW3 6JJ, UK.
Domenica LorussoGynaecological Oncology Unit, Catholic University of Rome & Fondazione Policlinico Gemelli IRCCS, Rome, 00168,Italy.

Funding

ImmunoGen
6 · The paper itself

Abstract

At first recurrence, platinum-sensitive ovarian cancer (PSOC) is frequently treated with platinum-based chemotherapy doublets plus bevacizumab, then single-agent bevacizumab. Most patients' disease progresses within a year after chemotherapy, emphasizing the need for novel strategies. Mirvetuximab soravtansine-gynx (MIRV), an antibody-drug conjugate, comprises a folate receptor alpha (FRα)-binding antibody and tubulin-targeting payload (maytansinoid DM4). In FRα-high PSOC, MIRV plus bevacizumab previously showed promising efficacy (objective response rate, 69% [95% CI: 41-89]; median progression-free survival, 13.3 months [95% CI: 8.3-18.3]; median duration of response, 12.9 months [95% CI: 6.5-15.7]) and safety. The Phase III randomized GLORIOSA trial will evaluate MIRV plus bevacizumab vs. bevacizumab alone as maintenance therapy in patients with FRα-high PSOC who did not have disease progression following second-line platinum-based doublet chemotherapy plus bevacizumab.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsBevacizumabFolate Receptor 1ImmunoconjugatesMaytansineOvarian NeoplasmsAntibodies, Monoclonal, HumanizedFemaleHumansMaintenance ChemotherapyPlatinumProgression-Free SurvivalAntibodies, Monoclonal, HumanizedBevacizumabFolate Receptor 1ImmunoconjugatesMaytansinemirvetuximab soravtansinePlatinumbevacizumabfolate receptor alphaGLORIOSA trialmaintenance therapymirvetuximab soravtansineplatinum-sensitive ovarian cancer

Identifiers

PMID39082675
PMCPMC11520569

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.